Vanguard Personalized Indexing Management LLC Has $803,000 Stake in Hims & Hers Health, Inc. $HIMS

Key Points

• Vanguard Personalized Indexing Management LLC has increased its stake in Hims & Hers Health, Inc. by 69.3%, now owning 16,102 shares valued at $803,000.
• Insider trading activity includes significant share sales by CFO Oluyemi Okupe and CEO Andrew Dudum, who sold 145,000 and 660,000 shares, respectively, with reductions in their holdings of 52.92% and 22.96%.
• Analyst ratings for Hims & Hers Health are predominantly neutral or negative, with several firms adjusting their target prices and maintaining a hold rating on the stock.

Vanguard Personalized Indexing Management LLC increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 69.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,102 shares of the company's stock after purchasing an additional 6,589 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Hims & Hers Health were worth $803,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Northern Trust Corp lifted its holdings in Hims & Hers Health by 19.5% during the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock worth $71,969,000 after purchasing an additional 397,310 shares during the last quarter. Yong Rong HK Asset Management Ltd lifted its holdings in Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock worth $70,920,000 after purchasing an additional 700,100 shares during the last quarter. Nuveen LLC acquired a new stake in Hims & Hers Health during the 1st quarter worth approximately $58,403,000. BIT Capital GmbH lifted its holdings in Hims & Hers Health by 7.4% during the 1st quarter. BIT Capital GmbH now owns 1,642,493 shares of the company's stock worth $48,536,000 after purchasing an additional 112,949 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Hims & Hers Health by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company's stock worth $37,242,000 after purchasing an additional 15,339 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Weiss Ratings reissued a "hold (c+)" rating on shares of Hims & Hers Health in a report on Tuesday, October 14th. Wall Street Zen lowered Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Truist Financial lowered their price objective on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. UBS Group set a $30.00 price objective on Hims & Hers Health in a research note on Monday, June 23rd. Finally, Zacks Research lowered Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Reduce" and a consensus price target of $38.92.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 145,000 shares of the business's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the transaction, the chief financial officer owned 128,984 shares of the company's stock, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the business's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares of the company's stock, valued at $112,023,016.02. This trade represents a 22.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,448,056 shares of company stock worth $75,139,240 over the last 90 days. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $51.40 on Tuesday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a 52 week low of $18.33 and a 52 week high of $72.98. The stock has a market capitalization of $11.62 billion, a P/E ratio of 64.25, a price-to-earnings-growth ratio of 3.39 and a beta of 2.25. The stock has a fifty day moving average of $51.04 and a 200-day moving average of $49.21.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period last year, the firm posted $0.06 EPS. Hims & Hers Health's quarterly revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.